The Robert & Maggie Bras and Family New Drug Development Program (BRAS DDP)
BRAS DDP at the Princess Margaret Cancer Centre in Toronto, is the largest program in Canada and one of the top five in the world!
We have had two decades of leading innovation and have received $60.6m peer-reviewed funding since 2001! The BRAS DDP is the only non-U.S. program to receive funding from the U.S. National Institute of Health (NIH).
Our program has a global impact on cancer research, by providing personalized cancer care, giving the right treatment to the right patient at the right time.
What drives us
Cancer is the leading cause of death, with 50% of all Canadians developing cancer in their lifetime, and 1 in 4 Canadians is expected to die from cancer. By 2028 to 2032 the average annual number of new cancer cases is estimated to increase by 79% compared to 2003 to 2007.
The BRAS DDP’s focus remains on high quality and timely trials with potential for significant impact. We are dedicated to conducting early phase clinical trials involving patients with advanced cancers. We can interrogate single and combination drug studies and incorporate robust translational endpoints to uncover underlying disease biology and agent mechanisms of action.
Thousands of people are diagnosed with cancer every year. There are on average 150 – 160 active clinical trials across all disease sites open at any one time, and more cancer patients become cancer survivors than ever before. There is always hope.
These are the stories of cancer patients - heroes who battled the disease and nurses and doctors who helped them on their journey.